Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]
News [4281]
Articles [400]
Editorials [10]
Conferences [107]
elearning [41]
Exchanging scientific information
Dr Phillipe Bedard - Breast International Group
Exchanging scientific information ( Dr Phillipe Bedard - Breast International Group )
12 Feb 2010
Bisphosphonates for breast cancer patients
Prof Michael Gnant - Medical University of Vienna, Austria
Bisphosphonates for breast cancer patients ( Prof Michael Gnant - Medical University of Vienna, Austria )
9 Feb 2010
Typical course for receptor positive early breast cancer
Dr Kimberly Blackwell - Duke University Medical Centre, USA
Typical course for receptor positive early breast cancer ( Dr Kimberly Blackwell - Duke University Medical Centre, USA )
9 Feb 2010
Oral bisphosphonate and breast cancer: prospective results from the Women's...
Dr Rowan Chlebowski - Harbor-University of California, Los Angeles
Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI) ( Dr Rowan Chlebowski - Harbor-University of California, Los Angeles )
28 Jan 2010
Use of bisphosphonates and risk of postmenopausal breast cancer
Dr Gad Rennert - Technion-Israel Institute of Technology, Israel
Use of bisphosphonates and risk of postmenopausal breast cancer ( Dr Gad Rennert - Technion-Israel Institute of Technology, Israel )
28 Jan 2010
Denosumab versus zoledronic acid for skeletal-related events in breast cancer...
Dr Alison Stopeck - University of Arizona Cancer Center
Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases ( Dr Alison Stopeck - University of Arizona Cancer Center )
28 Jan 2010
Short term biological effects of the combination of letrozole and zoledronic...
Prof Nigel Bundred - University of Manchester, UK
Short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer ( Prof Nigel Bundred - University of Manchester, UK )
28 Jan 2010
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase...
Prof Jenny Chang - Baylor College of Medicine, USA
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors ( Prof Jenny Chang - Baylor College of Medicine, USA )
28 Jan 2010
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor...
Dr Angelo Di Leo - Hospital of Prato, Italy
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Italy )
28 Jan 2010
Sorafenib in combination with paclitaxel for locally recurrent or metastatic...
Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA
Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer ( Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA )
28 Jan 2010
A novel strategy in treating endocrine resistance using combination therapy
Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San...
A novel strategy in treating endocrine resistance using combination therapy ( Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San Antonio, USA )
28 Jan 2010
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast...
Dr Kimberly Blackwell - Duke University Medical Center, USA
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, USA )
28 Jan 2010

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation